Dagliflozin and Rigliflozin both have the advantages of lowering blood glucose, low risk of hypoglycemia, and no weight gain, etc. However, Dagliflozin is prone to adverse reactions such as urinary tract infections, and Rigliflozin is prone to coughing, etc. Therefore, you cannot simply assess the advantages and disadvantages of the two and it is recommended to choose the medication under the guidance of a doctor. Dagliflozin is a sodium-glucose co-transporter protein 2 inhibitor, which inhibits sodium-glucose reabsorption in the proximal renal tubule and reduces blood glucose by increasing urinary glucose excretion. It has the advantages of low risk of hypoglycemia, weight loss, lower blood pressure, and potential cardiovascular benefit. Adverse effects of dagliflozin include urinary tract infection, genital infection, nasopharyngitis, etc. Contraindications are dagliflozin allergy, severe renal insufficiency and so on. Riglitazone is a dipeptidyl peptidase 4 inhibitor, which can increase the level of endogenous glucagon-like peptide-1, promote the secretion of insulin by β-cells and inhibit the secretion of glucagon by α-cells, so as to play the role of lowering glucose. It has the advantages of precise efficacy, good cardiovascular and renal safety, low risk of hypoglycemia, and no weight gain. Adverse effects of Riglitazone include cough, joint pain, and allergic reaction, etc. The contraindicated people are those who have a history of allergy to Riglitazone. Dagliflozin and Riglitazone are both prescription drugs, the specific choice of drugs and usage is recommended to strictly follow the doctor’s instructions.